J7627 HCPCS Level II code: Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
J7627 is the HCPCS code for “Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7627Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
Short description: Budesonide comp unit
HCPCS · United States
Medicare details
The indicators CMS publishes with J7627 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2006
Where J7627 sits
- 1J codesDrugs administered other than orally
- 2Active code J7627Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7627 mean?
J7627 is the HCPCS code for “Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7627?
CMS lists J7627’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7627
All J codesJ7614Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mgJ7615Levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mgJ7620Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dmeJ7622Beclomethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7624Betamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7626Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mgJ7628Bitolterol mesylate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7629Bitolterol mesylate, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7631Cromolyn sodium, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligramsJ7632Cromolyn sodium, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligramsJ7633Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligramJ7634Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligram